S155 The role of ST2 in a model of pulmonary hypertension

BackgroundPulmonary arterial hypertension (PAH) is a fatal condition involving remodelling of the pulmonary vessel wall leading to elevated pulmonary arterial pressure and eventually right heart failure. ST2 is a transmembrane receptor with ligand interleukin-33 (IL-33). p38 MAP kinase is an intrace...

Full description

Saved in:
Bibliographic Details
Published inThorax Vol. 65; no. Suppl 4; pp. A70 - A71
Main Authors Mahmood, A, McSharry, C, Xu, D, Peacock, A J, Welsh, D J
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and British Thoracic Society 01.12.2010
BMJ Publishing Group LTD
Online AccessGet full text

Cover

Loading…
Abstract BackgroundPulmonary arterial hypertension (PAH) is a fatal condition involving remodelling of the pulmonary vessel wall leading to elevated pulmonary arterial pressure and eventually right heart failure. ST2 is a transmembrane receptor with ligand interleukin-33 (IL-33). p38 MAP kinase is an intracellular signalling molecule shown to be involved in the vascular remodelling associated with PAH; and is also involved in ST2/IL-33 signalling. ST2/IL-33 signalling has been shown to reduce fibrosis in the heart following pressure overload in animal models.AimsTo determine whether ST2/IL-33 signalling was involved in the proliferation of mouse pulmonary artery fibroblasts and if p38 MAP kinase was involved.MethodsTwo cell types were used—wild type (WT) and ST2 knockout (ST2−/−) mouse pulmonary artery fibroblasts. Proliferation was assessed by [3H] Thymidine incorporation. Expression of p38 MAP kinase was detected by Western blotting. Cells were cultured at various serum concentrations in normoxia and hypoxia. A p38 MAP kinase inhibitor (SB203580) was used to assess its role in cell proliferation. The effect of IL-33 on cell proliferation and expression of p38 MAP kinase was studied.ResultsWT and ST2−/− cells proliferated in response to increasing serum concentration. WT cells hyperproliferated in response to hypoxia. ST2−/− cells hyperproliferated in normoxia and hypoxia compared to WT cells. The hyperproliferation of ST2−/− cells in normoxia and hypoxia could be reduced by p38 MAP kinase inhibition (p38) (see Abstract S155 Figure 1). Phosphorylated p38 MAP kinase was detected in all ST2−/− cells and in WT cells in hypoxia with 10% serum, demonstrating p38 MAP kinase is involved in the hyperproliferation observed. Hyperproliferation in response to hypoxia in WT cells could be blocked by addition of IL-33. IL-33 stimulation also decreased the phosphorylation of p38 MAP kinase. There was no effect of IL-33 on ST2−/− cells.Abstract S155 Figure 1Proliferation in Response to pp38 MAP Kinase Inhibition in Normoxia ST2-/- cells were cultured in normoxia at serum concentrations 0, 0.3, 1, 3, 5 and 10%, with and without the p38 MAP kinase inhibitor SB203580. Proliferation was reduced in the presence of the inhibitor with statistical significance at serum concentrations ?1% serum suggesting that p38 MAP kinase is involved in the hyperproliferation seen in ST2-/- cells.ConclusionsMouse pulmonary artery fibroblasts hyperproliferate in response to hypoxia and in the absence of the ST2 receptor. This hyperproliferation involves phosphorylation of p38 MAP kinase. This phosphorylation and excessive cell proliferation can be blocked by ST2/IL-33 signalling. ST2 may be a potentially novel therapeutic target in the PAH.
AbstractList Background Pulmonary arterial hypertension (PAH) is a fatal condition involving remodelling of the pulmonary vessel wall leading to elevated pulmonary arterial pressure and eventually right heart failure. ST2 is a transmembrane receptor with ligand interleukin-33 (IL-33). p38 MAP kinase is an intracellular signalling molecule shown to be involved in the vascular remodelling associated with PAH; and is also involved in ST2/IL-33 signalling. ST2/IL-33 signalling has been shown to reduce fibrosis in the heart following pressure overload in animal models. Aims To determine whether ST2/IL-33 signalling was involved in the proliferation of mouse pulmonary artery fibroblasts and if p38 MAP kinase was involved. Methods Two cell types were used—wild type (WT) and ST2 knockout (ST2−/−) mouse pulmonary artery fibroblasts. Proliferation was assessed by [3H] Thymidine incorporation. Expression of p38 MAP kinase was detected by Western blotting. Cells were cultured at various serum concentrations in normoxia and hypoxia. A p38 MAP kinase inhibitor (SB203580) was used to assess its role in cell proliferation. The effect of IL-33 on cell proliferation and expression of p38 MAP kinase was studied. Results WT and ST2−/− cells proliferated in response to increasing serum concentration. WT cells hyperproliferated in response to hypoxia. ST2−/− cells hyperproliferated in normoxia and hypoxia compared to WT cells. The hyperproliferation of ST2−/− cells in normoxia and hypoxia could be reduced by p38 MAP kinase inhibition (p38) (see Abstract S155 Figure 1). Phosphorylated p38 MAP kinase was detected in all ST2−/− cells and in WT cells in hypoxia with 10% serum, demonstrating p38 MAP kinase is involved in the hyperproliferation observed. Hyperproliferation in response to hypoxia in WT cells could be blocked by addition of IL-33. IL-33 stimulation also decreased the phosphorylation of p38 MAP kinase. There was no effect of IL-33 on ST2−/− cells. Proliferation in Response to pp38 MAP Kinase Inhibition in Normoxia ST2-/- cells were cultured in normoxia at serum concentrations 0, 0.3, 1, 3, 5 and 10%, with and without the p38 MAP kinase inhibitor SB203580. Proliferation was reduced in the presence of the inhibitor with statistical significance at serum concentrations ?1% serum suggesting that p38 MAP kinase is involved in the hyperproliferation seen in ST2-/- cells. Conclusions Mouse pulmonary artery fibroblasts hyperproliferate in response to hypoxia and in the absence of the ST2 receptor. This hyperproliferation involves phosphorylation of p38 MAP kinase. This phosphorylation and excessive cell proliferation can be blocked by ST2/IL-33 signalling. ST2 may be a potentially novel therapeutic target in the PAH.
Background Pulmonary arterial hypertension (PAH) is a fatal condition involving remodelling of the pulmonary vessel wall leading to elevated pulmonary arterial pressure and eventually right heart failure. ST2 is a transmembrane receptor with ligand interleukin-33 (IL-33). p38 MAP kinase is an intracellular signalling molecule shown to be involved in the vascular remodelling associated with PAH; and is also involved in ST2/IL-33 signalling. ST2/IL-33 signalling has been shown to reduce fibrosis in the heart following pressure overload in animal models. Aims To determine whether ST2/IL-33 signalling was involved in the proliferation of mouse pulmonary artery fibroblasts and if p38 MAP kinase was involved. Methods Two cell types were used-wild type (WT) and ST2 knockout (ST2-/-) mouse pulmonary artery fibroblasts. Proliferation was assessed by [3 H] Thymidine incorporation. Expression of p38 MAP kinase was detected by Western blotting. Cells were cultured at various serum concentrations in normoxia and hypoxia. A p38 MAP kinase inhibitor (SB203580) was used to assess its role in cell proliferation. The effect of IL-33 on cell proliferation and expression of p38 MAP kinase was studied. Results WT and ST2-/- cells proliferated in response to increasing serum concentration. WT cells hyperproliferated in response to hypoxia. ST2-/- cells hyperproliferated in normoxia and hypoxia compared to WT cells. The hyperproliferation of ST2-/- cells in normoxia and hypoxia could be reduced by p38 MAP kinase inhibition (p38) (see Abstract S155 Figure 1 ). Phosphorylated p38 MAP kinase was detected in all ST2-/- cells and in WT cells in hypoxia with 10% serum, demonstrating p38 MAP kinase is involved in the hyperproliferation observed. Hyperproliferation in response to hypoxia in WT cells could be blocked by addition of IL-33. IL-33 stimulation also decreased the phosphorylation of p38 MAP kinase. There was no effect of IL-33 on ST2-/- cells. Conclusions Mouse pulmonary artery fibroblasts hyperproliferate in response to hypoxia and in the absence of the ST2 receptor. This hyperproliferation involves phosphorylation of p38 MAP kinase. This phosphorylation and excessive cell proliferation can be blocked by ST2/IL-33 signalling. ST2 may be a potentially novel therapeutic target in the PAH.
BackgroundPulmonary arterial hypertension (PAH) is a fatal condition involving remodelling of the pulmonary vessel wall leading to elevated pulmonary arterial pressure and eventually right heart failure. ST2 is a transmembrane receptor with ligand interleukin-33 (IL-33). p38 MAP kinase is an intracellular signalling molecule shown to be involved in the vascular remodelling associated with PAH; and is also involved in ST2/IL-33 signalling. ST2/IL-33 signalling has been shown to reduce fibrosis in the heart following pressure overload in animal models.AimsTo determine whether ST2/IL-33 signalling was involved in the proliferation of mouse pulmonary artery fibroblasts and if p38 MAP kinase was involved.MethodsTwo cell types were used—wild type (WT) and ST2 knockout (ST2−/−) mouse pulmonary artery fibroblasts. Proliferation was assessed by [3H] Thymidine incorporation. Expression of p38 MAP kinase was detected by Western blotting. Cells were cultured at various serum concentrations in normoxia and hypoxia. A p38 MAP kinase inhibitor (SB203580) was used to assess its role in cell proliferation. The effect of IL-33 on cell proliferation and expression of p38 MAP kinase was studied.ResultsWT and ST2−/− cells proliferated in response to increasing serum concentration. WT cells hyperproliferated in response to hypoxia. ST2−/− cells hyperproliferated in normoxia and hypoxia compared to WT cells. The hyperproliferation of ST2−/− cells in normoxia and hypoxia could be reduced by p38 MAP kinase inhibition (p38) (see Abstract S155 Figure 1). Phosphorylated p38 MAP kinase was detected in all ST2−/− cells and in WT cells in hypoxia with 10% serum, demonstrating p38 MAP kinase is involved in the hyperproliferation observed. Hyperproliferation in response to hypoxia in WT cells could be blocked by addition of IL-33. IL-33 stimulation also decreased the phosphorylation of p38 MAP kinase. There was no effect of IL-33 on ST2−/− cells.Abstract S155 Figure 1Proliferation in Response to pp38 MAP Kinase Inhibition in Normoxia ST2-/- cells were cultured in normoxia at serum concentrations 0, 0.3, 1, 3, 5 and 10%, with and without the p38 MAP kinase inhibitor SB203580. Proliferation was reduced in the presence of the inhibitor with statistical significance at serum concentrations ?1% serum suggesting that p38 MAP kinase is involved in the hyperproliferation seen in ST2-/- cells.ConclusionsMouse pulmonary artery fibroblasts hyperproliferate in response to hypoxia and in the absence of the ST2 receptor. This hyperproliferation involves phosphorylation of p38 MAP kinase. This phosphorylation and excessive cell proliferation can be blocked by ST2/IL-33 signalling. ST2 may be a potentially novel therapeutic target in the PAH.
Author Mahmood, A
McSharry, C
Peacock, A J
Welsh, D J
Xu, D
Author_xml – sequence: 1
  givenname: A
  surname: Mahmood
  fullname: Mahmood, A
  organization: Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, UK
– sequence: 2
  givenname: C
  surname: McSharry
  fullname: McSharry, C
  organization: Dept of Immunology, University of Glasgow, Glasgow, UK
– sequence: 3
  givenname: D
  surname: Xu
  fullname: Xu, D
  organization: Dept of Immunology, University of Glasgow, Glasgow, UK
– sequence: 4
  givenname: A J
  surname: Peacock
  fullname: Peacock, A J
  organization: Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, UK
– sequence: 5
  givenname: D J
  surname: Welsh
  fullname: Welsh, D J
  organization: Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, UK
BookMark eNqNkM9Kw0AQxhepYFt9AG8Br6bO7ia7CZ4k-A9KFRp7XTabDU1NsnE3hfbmxRf1SUyIeBYGhhm-75vhN0OTxjQaoUsMC4wpu-m2hwWBYQohDumCnaApDljkUxKzCZoCBOAzytkZmjm3A4AIYz5Ft2scht-fX-lWe9ZU2jOFt06JVzae9GqT62rYtPuqNo20R297bLXtdONK05yj00JWTl_89jl6e7hPkyd_-fL4nNwt_YxQxvyA51iBJJQEKs4ViSPGFRAVSchyQgiToCDGRMcBxn0xYAHPFFNSyyLKKZ2jqzG3teZjr10ndmZvm_6kwDzCEcSMQK_Co0pZ45zVhWhtWfc_CwxiYCR6RmJgJEZGgvUef_SUrtOHP4O074JxykOx2iRi85oSslqFIun116M-q3f_iP8BzbJ2uQ
CODEN THORA7
CitedBy_id crossref_primary_10_1002_clc_22262
crossref_primary_10_1007_s12032_016_0880_3
crossref_primary_10_3390_life12030389
ContentType Journal Article
Copyright 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Copyright: 2010 (c) 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Copyright_xml – notice: 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
– notice: Copyright: 2010 (c) 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
DBID BSCLL
AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
BTHHO
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PQEST
PQQKQ
PQUKI
PRINS
DOI 10.1136/thx.2010.150953.6
DatabaseName Istex
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central
BMJ Journals
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
DatabaseTitle CrossRef
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
BMJ Journals
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
DatabaseTitleList
ProQuest One Academic Eastern Edition

Database_xml – sequence: 1
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-3296
EndPage A71
ExternalDocumentID 4027074491
10_1136_thx_2010_150953_6
ark_67375_NVC_VPT22NN5_C
GroupedDBID ---
.55
.GJ
.VT
08G
0R~
123
18M
29Q
2WC
354
39C
3O-
3V.
4.4
40O
53G
5RE
5VS
6PF
7X7
7~S
88E
8F7
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAYEP
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGTL
ACHTP
ACMFJ
ACOFX
ACTZY
ADBBV
ADCEG
ADZCM
AENEX
AFKRA
AFWFF
AHMBA
AHNKE
AHQMW
AJYBZ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
BAWUL
BENPR
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DU5
E3Z
EBS
EJD
F5P
FEDTE
FYUFA
GX1
H13
HAJ
HMCUK
HVGLF
HYE
HZ~
IAO
IEA
IH2
IHR
IOF
ITC
J5H
KQ8
L7B
M1P
N4W
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
R53
RHF
RHI
RMJ
RPM
RV8
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W8F
WH7
X7M
YFH
YOC
YQY
ZCG
ZGI
BSCLL
AAYXX
CITATION
7XB
8FK
K9.
PQEST
PQUKI
PRINS
ID FETCH-LOGICAL-b2366-47d1c0a2324c9dc29867c02c8a0bd2226a0c0912e941141160647bc6caeaf8d33
IEDL.DBID 7X7
ISSN 0040-6376
IngestDate Thu Oct 10 18:07:37 EDT 2024
Fri Aug 23 01:36:59 EDT 2024
Wed Oct 30 09:25:17 EDT 2024
Wed Aug 21 03:28:49 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Suppl 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b2366-47d1c0a2324c9dc29867c02c8a0bd2226a0c0912e941141160647bc6caeaf8d33
Notes href:thoraxjnl-65-A70-2.pdf
ArticleID:thoraxjnl150953.6
ark:/67375/NVC-VPT22NN5-C
istex:C4BADC9215B03EB81ACDFCD58308A9291B2FEADC
local:thoraxjnl;65/Suppl_4/A70-a
OpenAccessLink https://thorax.bmj.com/content/thoraxjnl/65/Suppl_4/A70.2.full.pdf
PQID 1781809620
PQPubID 2041050
ParticipantIDs proquest_journals_1781809620
crossref_primary_10_1136_thx_2010_150953_6
istex_primary_ark_67375_NVC_VPT22NN5_C
bmj_primary_10_1136_thx_2010_150953_6
PublicationCentury 2000
PublicationDate 20101200
2010-12
2010-12-01
20101201
PublicationDateYYYYMMDD 2010-12-01
PublicationDate_xml – month: 12
  year: 2010
  text: 20101200
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Thorax
PublicationTitleAlternate Thorax
PublicationYear 2010
Publisher BMJ Publishing Group Ltd and British Thoracic Society
BMJ Publishing Group LTD
Publisher_xml – name: BMJ Publishing Group Ltd and British Thoracic Society
– name: BMJ Publishing Group LTD
SSID ssj0008117
Score 2.0188828
Snippet BackgroundPulmonary arterial hypertension (PAH) is a fatal condition involving remodelling of the pulmonary vessel wall leading to elevated pulmonary arterial...
Background Pulmonary arterial hypertension (PAH) is a fatal condition involving remodelling of the pulmonary vessel wall leading to elevated pulmonary arterial...
SourceID proquest
crossref
istex
bmj
SourceType Aggregation Database
Publisher
StartPage A70
Title S155 The role of ST2 in a model of pulmonary hypertension
URI http://dx.doi.org/10.1136/thx.2010.150953.6
https://api.istex.fr/ark:/67375/NVC-VPT22NN5-C/fulltext.pdf
https://www.proquest.com/docview/1781809620
Volume 65
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS8MwFA7qQHwRrzhv5EF9EOpya7o-iQ6nCJahc-wtJGnLvLVzbjD_vSddOxFBfGybl35JzvlO8p1zEDqixqSWC-sx31hPxFZ74IYCj4g00HFqmsIWKt9I3jyK277fLw_cPkpZZWUTC0Md59adkTdo4LKSQ8nI-fDdc12j3O1q2UJjEdUoI9JJuoL-POAiLomyUs1J2EnlrSblsjEeTGe6LiBEoc_PXMkR8_b8wzvVHNDTX0a68DztNbRaUkZ8MZvjdbSQZBto-a68FN9E4QN4awzzjZ1UEOcpfugy_JRhjYs-N-7NcPIKP6BHn3gAgeeokK3n2RZ6bF91Wzde2RHBM4xL6YkgppZox4JsGFsWNmVgCbNNTUwMnl5qYoEAsCQUEOdQKl0qqbHS6kSnzZjzbbSU5VmygzCXBrgFxNXAUETIjeGhYMQY39UUCyiro2PAQw1nNS9UEStwqQA35XBTM9yUrKPTCrH_DD4pMJ2P1KMXpywLfBX1WqrX6TIWRb5q1dF-BboqN9WH-l4Cu39_3kMrbK462UdL49EkOQDuMDaHxQI5RLXLq6hzD0_XffoFZZO9eQ
link.rule.ids 315,783,787,12068,21400,27936,27937,31731,33756,43322,43817,74073,74630
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS8MwFA66gfoiXnE6NQ_qg1BtkzRtn0SGY-pWhHVjbyFJW-atnd0G89-b9DIRQXxt85IvyTnfSb5zDgBnlhCxxEQayBbSIKHkhnJDjmGS2OFhLFwic5WvTzsD8jCyR-WF27SUVVY2MTfUYSr1Hfm15eisZI8i82byYeiuUfp1tWyhsQrqug6X7mDgjJYBl6mTKCvVHFUnqXzVtDC9no0Xha5LESLPxle65Ih4f_nhneoa6MUvI517nvYW2CwpI7wt1ngbrETJDljrlY_iu8DrK28N1XpDLRWEaQz7AYLPCeQw73Ojv0zmb2oCPPuEYxV4ZrlsPU32wKB9F7Q6RtkRwRAIU2oQJ7SkyTULkl4okedSR5pIutwUofL0lJtSEQAUeUTFOZZFdSqpkFTyiMduiPE-qCVpEh0AiKlQ3ELF1YqhEA8LgT2CTCFsXVPMsVADnCs82KSoecHyWAFTpnBjGjdW4MZoA1xWiP1n8EWO6XIkz161ssyxmT9sseFTgJDv26zVAM0KdFYeqin73gKHf_8-BeudoNdl3Xv_8QhsoKUCpQlqs2weHSseMRMn-Wb5Avn6vdU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT8MwDLZgkxAXxFOMZw7AAamsTdJ0PSEYTDyrCQbiFiVpK57dGEOCf4_TZUMICXFtc-mXxP5cf7YBtgKtc8O48WiojcdTozx0Q5Hn8zxSaa4b3JQq30Sc3PCzu_DO6Z_enKxyZBNLQ512jf1HXg8iW5UcC-rXcyeLaB-19nuvnp0gZTOtbpzGJFQjLphfgerhcdK-GttlW1I50tAJvFcuxxkwUR_cfwxVXkiP4pDt2QYk-uXxh6-qWtg_fpns0g-1ZmHGEUhyMNzxOZjIinmYunQp8gWIr9F3E9x9YoWDpJuT6w4lDwVRpJx6Y5_03p_xE1T_k9xjGNovRezdYhFuWsed5onn5iN4mjIhPB6lgfGV5UQmTg2NGyIyPjUN5esU_b5QvkE6QLOYY9QTBMIWlmojjMpU3kgZW4JK0S2yZSBMaGQaGGUjX-Ex05rFnPpah7bDWBTQGmwjHrI37IAhy8iBCYm4SYubHOImRQ12R4j9Z_FOiel4peo_WZ1ZFMrktilv2x1KkySUzRqsjUCX7oq9ye8DsfL3602YwpMiL06T81WYpmM5yhpUBv33bB1JxUBvuNPyBY73w3I
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=S155%E2%80%85The+role+of+ST2+in+a+model+of+pulmonary+hypertension&rft.jtitle=Thorax&rft.au=Mahmood%2C+A&rft.au=McSharry%2C+C&rft.au=Xu%2C+D&rft.au=Peacock%2C+A+J&rft.date=2010-12-01&rft.pub=BMJ+Publishing+Group+Ltd+and+British+Thoracic+Society&rft.issn=0040-6376&rft.eissn=1468-3296&rft.volume=65&rft.issue=Suppl+4&rft.spage=A70&rft_id=info:doi/10.1136%2Fthx.2010.150953.6&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_NVC_VPT22NN5_C
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0040-6376&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0040-6376&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0040-6376&client=summon